Prophylaxis of schizoaffective disorder with lithium or carbamazepine: Outcome after long-term follow-up

Journal of Affective Disorders

Volumn 79, Issue 1-3, 2004, Pages 43-50

  Baethge, Christopher ^a   Gruschka, Philipp ^b   Berghöfer, Anne ^c   Bauer, Michael ^d   Müller Oerlinghausen, Bruno ^e   Bschor, Tom ^f   Smolka, Michael N ^g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Drug Commission of the German Medical Association   (Germany)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Latency; Lithium; Predictors; Prophylaxis; Schizoaffective disorder

Indexed keywords

CARBAMAZEPINE; LITHIUM;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG BLOOD LEVEL; FAMILY HISTORY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LATENT PERIOD; LENGTH OF STAY; MAINTENANCE THERAPY; MAJOR DEPRESSION; MALE; MORBIDITY; ONSET AGE; PREDICTION; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; RECURRENT DISEASE; SCHIZOAFFECTIVE PSYCHOSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTIMANIC AGENTS; CARBAMAZEPINE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LITHIUM CARBONATE; MALE; PROGNOSIS; PSYCHOTIC DISORDERS; RISK FACTORS; TREATMENT OUTCOME;

EID: 1542614032     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(02)00354-3     Document Type: Article

References (32)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition - revised :1987;American Psychiatric Association, Washington, DC.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition :1994;American Psychiatric Association, Washington, DC.
3. Angst J., Weis P., Grof P., Baastrup C., Schou M. Lithium prophylaxis in recurrent affective disorders. Br. J. Psychiatry. 116:1970;604-613.
4. Angst J., Preisig M. Course of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985. Schweiz Arch. Neurol. Psychiatr. 146:1995;5-16.
5. Angst J., Preisig M. Outcome of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985. Schweiz Arch. Neurol. Psychiatr. 146:1995;17-23.
6. Baethge C. Long-term Treatment of Schizoaffective Disorder: Review and recommendations. Pharmacopsychiatry. 2003;. in press.
7. Baethge, C., Smolka, M.N., Gruschka, P., Berghöfer, A., Schlattmann, P., Bauer, M., Altshuler, L., Grof, P., Müler-Oerlinghausen, B., 2003. Does prophylaxis-delay in bipolar disorder influence outcome? Results from a long-term study of 147 patients. Acta Psychiatr. Scand., in press.
8. Baldessarini R.J., Tohen M., Tondo L. Maintenance treatment in bipolar disorder. Arch. Gen. Psychiatry. 57:2000;490-492.
9. Baldessarini R.J., Tondo L., Hennen J., Floris G. Latency and episodes before treatment: response to lithium maintenance in bipolar I and II disorders. Bipolar Disord. 2:1999;91-97.
10. Berghöfer A., Kossmann B., Müller-Oerlinghausen B. Course of illness and pattern of recurrences in patients with affective disorders during long-term lithium prophylaxis: a retrospective analysis over 15 years. Acta Psychiatr. Scand. 93:1996;349-354.
11. Bouman T.K., Niemantsverdriet-van Kampen J.K., Ormel J., Sloof C.J. The effectiveness of lithium prophylaxis in bipolar and unipolar depressions and schizoaffective disorders. J. Affect. Disord. 11:1986;275-280.
12. Calabrese J.R., Fatemi S.H., Kujawa M., Woyshville M.J. Predictors of response to mood stabilizers. J. Clin. Psychopharmacol. 16:(Suppl. 1):1996;24S-31S.
13. Coppen A., Abou-Saleh M.T. Plasma folate and affective morbidity during long-term lithium therapy. Br. J. Psychiatry. 141:1982;87-89.
14. Greil W., Ludwig-Mayerhofer W., Erazo N., Engel R.R., Czernik A., Giedcke H., Müller-Oerlinghausen B., Osterheider M., Rudolf G.A.E., Sauer H., Tegeler J., Wetterling T. Lithium vs. carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study. Eur. Arch. Psychiatry Clin. Neurosci. 247:1997;42-50.
15. Grof P., Alda M., Grof E., Fox D., Cameron P. The challenge of predicting response to stabilizing lithium treatment. Br. J. Psychiatry. 163:(Suppl. 21):1993;16-19.
16. Larsen T.K., Friis S., Haahr U., Joa I., Johannessen J.O., Mell I., Opjordsmoen S., Simonsen E., Vaglum P. Early detection and intervention in first-episode schizophrenia: a critical review. Acta Psychiatr. Scand. 103:2001;323-334.
17. Levinson D.F., Umapathy C., Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am. J. Psychiatry. 156:1999;1138-1148.
18. Maj M. Lithium prophylaxis of schizoaffective disorders: a prospective study. J. Affect. Disord. 14:1988;129-135.
19. Marneros A., Deister A., Rohde A. Stability of diagnoses in affective, schizoaffective and schizophrenic disorders: cross sectional versus longitudinal diagnosis. Eur. Arch. Psychiatry Clin. Neurosci. 241:1991;187-192.
20. Mattes J.A., Nayak D. Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives. Biol. Psychiatry. 19:1984;445-449.
21. McElroy S.L., Keck P.E., Strakowski S.M. An overview of the treatment of schizoaffective disorder. J. Clin. Psychiatry. 60:(Suppl. 5):1999;16-21.
22. Müller-Oerlinghausen B., Ahrens B., Grof E., Grof P., Lenz G., Schou M., Simhandl C., Thau K., Volk J., Wolf R., Wolf T. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr. Scand. 86:1992;218-222.
23. Perris C. Morbidity suppressive effect of lithium carbonate in cycloid psychosis. Arch. Gen. Psychiatry. 35:1978;328-331.
24. Post R. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am. J. Psychiatry. 149:1992;999-1010.
25. Robinson D.G., Woerner M.G., Alvir J.M.J., Bilder R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Lieberman J.A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry. 56:1999;241-247.
26. Sarantidis D., Waters B. Predictors of lithium prophylaxis effectiveness. Prog. Neurol. Psychopharmacol. 5:1981;507-510.
27. Spitzer R.L., Endicott J., Robins E. Research Diagnostic Criteria (RDC) for a Selected Group of Functional Disorders. 3rd Edition :1978;New York State Biometric Institute Biometrics Research, New York.
28. Taylor M.A. The validity of schizoaffective disorders: treatment and prevention studies. Marneros A., Tsuang M.T. Schizoaffective Psychoses. 1986;94-114 Springer, Berlin.
29. Tsuang M.T., Simpson J.C., Fleming J.A. Schizoaffective disorders. Henn F., Sartorius N., Helmchen H., Lauter H. Contemporary Psychiatry. Vol. 3:2001;399-413 Springer, New York.
30. Tondo L., Baldessarini R.J., Floris G. Long-term effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br. J. Psychiatry. 178:(Suppl. 41):2001;s184-s190.
31. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders, Clinical Descriptions and Diagnostic Guidelines. 1992;World Health Organization, Geneva.
32. Wyatt R.J. Early Intervention for schizophrenia: Can the course of the illness be altered? Biol. Psychiatry. 8:1995;1-3.